The RIO study is looking at whether a new type of treatment called the monoclonal broadly neutralising antibodies (‘bNAbs’) can keep viral load undetectable without antiretroviral treatment (ART). This will involve asking all patients to stop ART for a short time

The study will measure how long viral load stays undetectable in a blood test without ART. It will also look at what happens to the HIV virus and immune system in blood samples. When virus becomes detectable in a blood test (‘viral rebound’) you will be asked to re-start your ART.

RIO is funded by the Bill & Melinda Gates Foundation. Imperial College London is the trial Sponsor, and the trial is coordinated by Imperial College London, the University of Oxford, and The Rockefeller University.

We aim to recruit 72 adult patients across 10 NHS sites in England and Scotland. A new site may also open in Denmark.

Please visit the RIO Trial website or the Health Research Authority RIO web page for more information.